Master donor viruses A/Leningrad/134/17/57 (H2N2) and B/USSR/60/69 and derived reassortants used in live attenuated influenza vaccine (LAIV) do not display neurovirulent properties in a mouse model

Voeten, J.T.M.; Kiseleva, Irina; Glansbeek, Harrie L.; Basten, Stephanie M. C.; Cruijsen, Sandra K. M. Drieszen-van der; Rudenko, Larisa; Bosch, Han van den; Heldens, Jacco

doi:10.1007/s00705-010-0719-8

Cited by 6 publications

(3 citation statements)

References 22 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…d No virus was detected in the brain tissues of mice from any of the groups. e P Ͻ 0.05 compared to Len134 virus. in the lower respiratory tract is consistent with virulence attenuation for mice (42).…”

Section: Replication Of Original and Rg-derived H2n2 Viruses In Micesupporting

confidence: 70%

Characterization of Reverse Genetics-Derived Cold-Adapted Master Donor Virus A/Leningrad/134/17/57 (H2N2) and Reassortants with H5N1 Surface Genes in a Mouse Model

Isakova–Sivak¹,

Chen²,

Bourgeois³

et al. 2014

Clin. Vaccine Immunol.

Self Cite

View full text Add to dashboard Cite

Section: Replication Of Original and Rg-derived H2n2 Viruses In Micesupporting

confidence: 70%

Characterization of Reverse Genetics-Derived Cold-Adapted Master Donor Virus A/Leningrad/134/17/57 (H2N2) and Reassortants with H5N1 Surface Genes in a Mouse Model

Isakova–Sivak¹,

Chen²,

Bourgeois³

et al. 2014

Clin. Vaccine Immunol.

Self Cite

View full text Add to dashboard Cite

“…Currently, three cold-adapted influenza A virus strains -A/ Ann Arbor/6/60 (AA) (H2N2), A/Leningrad/134/17/57 (H2N2) and A/Leningrad/134/47/57 (H2N2)and two B virus strains -B/Ann Arbor/1/66 ca and B/USSR/60/69 cahave been developed to use as LAIV donor viruses to generate appropriate seasonal influenza vaccines. 6,7 However, there is no H1N1 sub-type strain. In 2003, the Food and Drug Administration (FDA) approved FluMist (MedImmune), by first using LAIV, which employed the cold adapted donor strains A/Ann Arbor/6/60 (H2N2) and B/Ann Arbor/1/66 ca.…”

Section: Introductionmentioning

confidence: 99%

Preparation and evaluation of a novel, live, attenuated influenza H1N1 vaccine strain produced by a modified classical reassortment method

Long

Liu

Song

et al. 2017

Human Vaccines & Immunotherapeutics

View full text Add to dashboard Cite

Live attenuated influenza vaccine (LAIV)-based Vero cells could provide a better choice to control and prevent influenza virus infections. This study used the human influenza virus A/Yunnan/1/2005Vca(H3N2) (YN/05Vca) as a donor strain. YN/05Vca has a double phenotype of cold adaption (ca) and Vero cell adaption (va). The parental virus strain used was the wild-type A/Solomon Islands/3/2006 (H1N1) (SI/06wt). The study employed the modified classical reassortment method to generate a new virus strain. After co-infection of Vero cells, some different sub-types of the reassorted viruses were generated randomly. Then, the specific anti-serum (anti-YN/05Vca) could combine with and neutralize the donor virus, and the original parental virus could not grow in Vero cells at a low temperature until it was re-structured with the meaningful gene fragment from the donor virus in Vero cells. According to the plaques and RT-PCR results, a new monoclonal strain of Vero cell cold adaption virus was screened: SI/06Vca. After immunological and biological identification, this new strain virus could be used as a seed bank for LAIV, which has maintained surface antigenicity with SI/06wt. Consequently, this new Vero cell cold adaption virus SI/06Vca could be used for large-scale vaccine production with sufficient safety and efficacy, as confirmed by animal experiments with mice and ferrets.

show abstract

“…The LAIV consists of reassortant viruses, which contain hemagglutinin (HA) and neuraminidase (NA) gene segments from circulating wild-type (WT) viruses of interest on a backbone of the remaining six internal protein genes derived from the attenuated master donor viruses (MDVs) (genomic composition 6 MDV genes: 2 WT genes). A/Leningrad/134/17/57 (H2N2) (Len-MDV) and B/USSR/60/69 MDVs are currently used in Russia as MDVs for LAIV [6]. Although LAIVs have been under Reassortants for Russian LAIV are being produced by the Institute of Experimental Medicine (IEM, St Petersburg, Russia).…”

Section: Introductionmentioning

confidence: 99%

New Methodological Approaches in The Development of Russian Live Attenuated Vaccine for Pandemic Influenza

Kiseleva¹,

Larionova²,

Федорова³

et al. 2015

Transl Biomed

View full text Add to dashboard Cite

Avian influenza viruses remain a major pandemic threat. In response to this threat, a number of pandemic vaccines have been developed. The objective of this paper is to review and summarize data from preclinical and clinical evaluation of Russian live attenuated influenza vaccines (LAIVs) against pandemic influenza based on cold-adapted A/Leningrad/134/17/57 (H2N2) master donor virus (MDV). The described LAIVs consist of reassortant viruses of 6:2 and 7:1 genomic composition (6 MDV genes: 2 WT genes and 7 MDV genes: 1 WT gene, respectively). Despite the differences in their genomic composition (6:2 or 7:1), LAIV candidates of H5, H7 and H2 subtypes acquired temperature sensitivity, cold-adaptation, and attenuation for different animal models. In addition, they were safe and immunogenic for healthy adult volunteers. The collected data indicate that 7:1 reassortants carrying HA genes of potentially pandemic viruses and the remaining genes from the MDV might be preferable pandemic LAIV candidates.

show abstract

Master donor viruses A/Leningrad/134/17/57 (H2N2) and B/USSR/60/69 and derived reassortants used in live attenuated influenza vaccine (LAIV) do not display neurovirulent properties in a mouse model

Cited by 6 publications

References 22 publications

Characterization of Reverse Genetics-Derived Cold-Adapted Master Donor Virus A/Leningrad/134/17/57 (H2N2) and Reassortants with H5N1 Surface Genes in a Mouse Model

Characterization of Reverse Genetics-Derived Cold-Adapted Master Donor Virus A/Leningrad/134/17/57 (H2N2) and Reassortants with H5N1 Surface Genes in a Mouse Model

Preparation and evaluation of a novel, live, attenuated influenza H1N1 vaccine strain produced by a modified classical reassortment method

New Methodological Approaches in The Development of Russian Live Attenuated Vaccine for Pandemic Influenza

Contact Info

Product

Resources

About